Amarantus
Amarantus Reacquires Neurology Diagnostic Assets from Avant
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
Avant Completes Acquisitions of Amarantus, Theranostics Health
The deals bring together Avant's ovarian cancer diagnostic, Amarantus' multiple sclerosis and Alzheimer's disease assays, and Theranostics' CLIA lab.
The deal brings together three firms that have struggled to ramp their test businesses in hopes that the combined outfit will be better positioned to succeed.
Avant, Amarantus Diagnostics Add Theranostics Health to Planned Merger
Avant and Amarantus, which agreed to merge in January, have now signed a deal to acquire Theranostics Health and its CLIA-certified laboratory.
Amarantus Inks Deal to Merge Dx Unit with Avant Diagnostics
When the merger is complete, Amarantus will own 80 million shares of Avant, representing about 45 percent of the combined company.
Apr 27, 2015
Amarantus Bio Raises $5M
Jan 13, 2015